Surmodics, Inc. (SRDX)
NASDAQ: SRDX · Real-Time Price · USD
29.99
+0.99 (3.41%)
Jul 3, 2025, 1:00 PM - Market closed
Surmodics Employees
Surmodics had 389 employees as of September 30, 2024. The number of employees increased by 13 or 3.46% compared to the previous year.
Employees
389
Change (1Y)
13
Growth (1Y)
3.46%
Revenue / Employee
$312,532
Profits / Employee
-$51,062
Market Cap
428.83M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
SRDX News
- 2 months ago - Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance - Business Wire
- 2 months ago - Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30 - Business Wire
- 2 months ago - Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon - Business Wire
- 3 months ago - Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries - Business Wire
- 4 months ago - Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR - Business Wire
- 4 months ago - FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics - Reuters
- 5 months ago - Top 3 Health Care Stocks You'll Regret Missing This Month - Benzinga
- 5 months ago - Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries - Business Wire